The strongest version of this narrative is that BIO-Europe Spring 2026 represents a pivotal moment for European biopharma, showcasing innovation and resilience amid funding challenges. The event highlights the continent’s growing capacity to compete globally, particularly in underserved regions like southern Europe, while addressing critical gaps in women’s health, rare diseases, and emerging therapies. The optimism is grounded in tangible advancements—such as Vesper Bio’s neurodegeneration rese...